
    
      The study will the investigators develop in The Tropical Medicine Institute Alexander von
      Humboldt that is a referral center in Peru for diseases associated to Human T-Lymphotropic
      Virus 1 Infection (HTLV-1). The Institute has a cohort of around 600 patients currently being
      followed up and around 20 to 25 new patients are admitted every year with this disease.

      This is a pilot study of intervention in a group of patients with tropical spastic
      paraparesis/ myelopathy to evaluate virologic and clinical response of raltegravir plus
      zidovudine in this group of patients on the follow-up of 48 weeks.
    
  